Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q00722
UPID:
PLCB2_HUMAN
Alternative names:
Phosphoinositide phospholipase C-beta-2; Phospholipase C-beta-2
Alternative UPACC:
Q00722; A8K6J2; B9EGH5
Background:
The 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-2, also known as Phosphoinositide phospholipase C-beta-2 or Phospholipase C-beta-2, plays a pivotal role in cellular processes. It is instrumental in the production of second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3), which are crucial for the transduction of extracellular signals.
Therapeutic significance:
Understanding the role of 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-2 could open doors to potential therapeutic strategies. Its involvement in signal transduction pathways offers a promising avenue for the development of novel treatments.